>

>

The Hidden Tax of “One More System”

The Hidden Tax of “One More System”

There’s an assumption in clinical trials that doesn’t get challenged nearly enough: If each system is good… then more systems must be better. More specialised. More powerful. More “best-of-breed”. But spend a day at a clinical trial site, and that logic starts to unravel.

There’s an assumption in clinical trials that doesn’t get challenged nearly enough:

If each system is good… then more systems must be better.

More specialised. More powerful. More “best-of-breed”.

But spend a day at a clinical trial site, and that logic starts to unravel.


The Morning Ritual Nobody Designed

A site coordinator logs in.

Not once. But six times.

Different usernames. Different passwords. Different mental models.

One system to randomise. Another to capture data. Another to manage outcomes. Another to track visits.

And before a single patient is seen, the day has already begun with friction.

This isn’t anecdotal.

Studies and industry initiatives consistently highlight that fragmented systems and poor usability increase workload, errors, and inefficiencies at the site level.

And here’s the uncomfortable part:

None of these systems are broken.


This Is Not a Workload Problem

When sites struggle, the default diagnosis is predictable:

“They’re under-resourced.” “They need more training.” “They need better discipline.”

But that misses the point entirely.

Because the issue isn’t the amount of work. It’s the shape of the work.

When identical tasks — screening, enrolling, scheduling, reporting — are executed differently across every study…

You’re not increasing rigour.

You’re increasing cognitive load.


The Cognitive Tax We Don’t Measure

There’s a hidden cost in clinical trials that never appears in budgets:

The mental overhead of remembering how each study works.

Which system handles what? Which login applies here? Which workflow comes next?

It’s small, individually.

But across:

  • 5+ systems

  • Multiple concurrent studies

  • Repeated training cycles

  • Hundreds of daily micro-decisions

…it compounds into something much bigger:

Decision fatigue. Delay. And ultimately, risk.

ICH E6(R3) explicitly reinforces that systems used in trials must be fit for purpose and usable, recognising that poor design directly impacts quality and execution.


When Innovation Becomes Multiplication

The industry often celebrates adding new technology:

New eCOA. New IRT. New EDC. New portal.

But rarely do we ask:

What happens when you layer them together?

Because from a sponsor perspective, each addition solves a problem.

From a site perspective, each addition creates one.

And over time, innovation stops looking like progress…

…and starts looking like duplication.


We Didn’t Design for the End User

Here’s the core truth:

Clinical trial systems are rarely designed around how work actually happens at the site level.

They’re designed around:

  • Study needs

  • Vendor capabilities

  • Procurement decisions

  • Functional silos


But not the person who has to make it all work together.

So the burden shifts.

From system → to human.

From architecture → to memory.

From design → to improvisation.


The Future Isn’t Fewer Systems

Let’s be clear:

The answer isn’t to eliminate systems.

Clinical trials are complex. Different functions require different capabilities.

The answer is something more fundamental:

Consistency. Coordination. Orchestration.

A world where:

  • One login replaces many

  • One workflow guides the process

  • One interface simplifies the day

Not by removing systems…

…but by making them behave as one.


The Real Question

We’ve spent years asking:

“Which system is best?”

Maybe it’s time to ask something better:

“What does this feel like to run?”

Because until we design clinical trials for the people actually delivering them…

We’re not reducing complexity.

We’re just moving it around.


References

  1. TransCelerate BioPharma Inc. (2020–2023). Site Experience Initiative (SEI) https://www.transceleratebiopharmainc.com/initiatives/site-experience/

  2. International Council for Harmonisation (ICH). (2023). ICH E6(R3) Good Clinical Practice Guideline https://www.ich.org/page/efficacy-guidelines

  3. Tufts Center for the Study of Drug Development. Protocol complexity and its impact on clinical trial execution https://csdd.tufts.edu

  4. Cousins, J. (2026). Clinical trial site burden discussion - https://www.linkedin.com/posts/jonathan-cousins_we-dont-talk-enough-about-the-reality-of-activity-7422938627619434496-Qga2?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAWelmEBXz3yNZYWcXWv4VT15piuKJ8cK7E

About

Delivering independent journalism, thought-provoking insights, and trustworthy reporting to keep you informed, inspired, and engaged with the world every day.

Related Post

Mar 26, 2026

/

Post by

How to fix fragmentation without pretending it doesn’t exist

Mar 23, 2026

/

Post by

There’s a quiet lie circulating in clinical trials. It’s dressed up as sophistication. It sounds like maturity. It often appears in RFPs.

Feb 23, 2026

/

Post by

Clinical trial start-up — the phase encompassing vendor onboarding, system build and configuration, site activation and training — persistently consumes time, introduces friction and contributes to costly delays in getting first patient in. For decades this has been driven by an industry-wide reliance on narrative, unstructured protocols and disconnected operational hand-offs.

Jan 29, 2026

/

Post by

Why clinical trial technology buyers and sellers need to step up in 2026 In case you’ve been living under a rock - or buried under a pile of protocols - there’s a meme doing the rounds on LinkedIn and X that goes something like this: “I just had a deeply personal life experience… and here’s what it taught me about B2B sales.”

Dec 12, 2025

/

Post by

If you want to understand where clinical trials are heading, don’t start with conferences or consensus papers. Start with the one thing that never lies: capital allocation.

Dec 11, 2025

/

Post by

If clinical trials were a game of Where’s Waldo?, eligibility criteria would be Waldo’s sunglasses: tiny, easy to miss, and capable of derailing your search if you overlook them. For decades, finding the right participants i.e. the people who actually meet the labyrinthine inclusion and exclusion rules, has been a slow, painstaking quest. And while sites and sponsors pour hours of human effort into sifting through charts, an elephant has quietly stepped into the room wearing a speed-boosted jersey: artificial intelligence.

Mar 26, 2026

/

Post by

How to fix fragmentation without pretending it doesn’t exist

Mar 23, 2026

/

Post by

There’s a quiet lie circulating in clinical trials. It’s dressed up as sophistication. It sounds like maturity. It often appears in RFPs.

Feb 23, 2026

/

Post by

Clinical trial start-up — the phase encompassing vendor onboarding, system build and configuration, site activation and training — persistently consumes time, introduces friction and contributes to costly delays in getting first patient in. For decades this has been driven by an industry-wide reliance on narrative, unstructured protocols and disconnected operational hand-offs.

Jan 29, 2026

/

Post by

Why clinical trial technology buyers and sellers need to step up in 2026 In case you’ve been living under a rock - or buried under a pile of protocols - there’s a meme doing the rounds on LinkedIn and X that goes something like this: “I just had a deeply personal life experience… and here’s what it taught me about B2B sales.”

The eClinical Edge is an independent voice focused on the technology, systems, and decisions shaping modern clinical trials.

© 2026 The eClinical Edge. All rights reserved.

The eClinical Edge is an independent voice focused on the technology, systems, and decisions shaping modern clinical trials.

© 2026 The eClinical Edge. All rights reserved.

The eClinical Edge is an independent voice focused on the technology, systems, and decisions shaping modern clinical trials.

© 2026 The eClinical Edge. All rights reserved.